Related Experiment Videos
Inhibition of lymph node metastasis of P388 leukemia by bestatin in mice
Abstract:
Bestatin, a chemically defined immunostimulant of low molecular weight, suppressed the gradually-occurring lymph node metastasis of P388 leukemia in CDF1 mice when administered i.p. at the doses of 1 approximately 30 micrograms/mouse. It could not, however, suppress the established large metastasis of P388 leukemia. Lymph node cells isolated from the mice given bestatin i.p. at 1 and 30 microgram/mouse showed cytostatic activity against P388 leukemic cells in vitro than those from the untreated mice.
Insights
Bestatin, an immunostimulant, prevented the spread of P388 leukemia in mice but did not affect existing tumors. Lymph node cells from treated mice showed increased activity against leukemia cells.
Area of Science:
- Immunology
- Pharmacology
- Oncology
Background:
- P388 leukemia is a model for studying cancer metastasis.
- Immunostimulants are investigated for their potential in cancer therapy.
- Bestatin is a known immunostimulant with potential therapeutic applications.
Purpose of the Study:
- To investigate the effect of bestatin on P388 leukemia metastasis in vivo.
- To evaluate the impact of bestatin on the immune response against P388 leukemia cells.
Main Methods:
- Administration of bestatin to CDF1 mice with P388 leukemia.
- Assessment of lymph node metastasis development.
- In vitro evaluation of lymph node cell cytostatic activity against P388 leukemia cells.
Main Results:
- Bestatin suppressed the gradual development of lymph node metastasis at doses of 1-30 micrograms/mouse.
- Established, large metastases were not suppressed by bestatin treatment.
- Lymph node cells from bestatin-treated mice exhibited enhanced cytostatic activity against P388 leukemia cells in vitro.
Conclusions:
- Bestatin demonstrates efficacy in preventing early-stage lymph node metastasis of P388 leukemia.
- Bestatin enhances immune cell activity, suggesting an immunomodulatory mechanism in cancer treatment.
- The timing and stage of metastasis are critical factors for bestatin's therapeutic effect.